Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bayer Aktienges ADR
(OP:
BAYRY
)
7.810
+0.130 (+1.69%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bayer Aktienges ADR
< Previous
1
2
3
4
5
6
Next >
BAYRY Stock Earnings: Bayer Meets EPS, Beats Revenue for Q2 2024
August 06, 2024
BAYRY stock results show that Bayer met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer
July 25, 2024
Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance that product is safe.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Glyphosate
Legal
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
July 08, 2024
Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery.
Via
InvestorPlace
3 Small-Cap Stocks With Explosive 2X Growth Potential
July 08, 2024
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.
Via
InvestorPlace
Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M
June 05, 2024
Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation.
Via
Benzinga
Exposures
Glyphosate
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
June 01, 2024
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in...
Via
Talk Markets
European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday?
May 27, 2024
European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW, Enel, Iberdrola.
Via
Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
May 24, 2024
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.
Via
Benzinga
Topics
Data Breach
Exposures
Information Security
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
May 17, 2024
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo.
Via
Benzinga
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16, 2024
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...
Via
Benzinga
BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q1 2024
May 14, 2024
BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
From Hype To Reality, AI Reshapes Pharmaceutical Industry Across Drug Discovery To Marketing - Stocks To Watch
May 10, 2024
Unlock the potential of AI in pharmaceuticals. With AI's help, the pharma industry could see $60B-$110B in annual economic value. Dive into the future of drug discovery and clinical development with...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned
May 02, 2024
Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict over chemical contamination. This highlights broader legal battles over PCBs...
Via
Benzinga
Exposures
Glyphosate
Alphabet, Nasdaq, Spotify, Teck Resources And A Major Financial Stock On CNBC's 'Final Trades'
April 10, 2024
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Nasdaq, Inc. (NASDAQ: NDAQ) is
Via
Benzinga
Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists
April 09, 2024
Unlock AI-powered radiology solutions with Bayer AG and Google Cloud collaboration. Accelerate medical imaging innovations with gen AI tools for faster diagnoses.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds
April 05, 2024
Corporate bonds offer yield opportunities and diversification away from equity investments. Investment-grade bonds are safer but lower yield, while high-yield bonds offer higher returns but from...
Via
Benzinga
Topics
Bonds
Exposures
Debt Markets
Bayer-Backed Boundless Bio Falls After IPO
March 31, 2024
Shares of Boundless Bio fell almost 10% after raising about $100 million in the company's initial public offering. Bayer is one of the biggest investors for the therapeutics company.
Via
Talk Markets
Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant
March 19, 2024
Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential...
Via
Benzinga
Exposures
Product Safety
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
March 14, 2024
Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications.
Via
Benzinga
Topics
Bankruptcy
Lawsuit
Exposures
Financial
Glyphosate
Legal
BAYRY Stock Earnings: Bayer Beats EPS, Misses Revenue for Q4 2023
March 05, 2024
BAYRY stock results show that Bayer beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges
March 05, 2024
Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing performance and flexibility. The company's focus and fiscal outlook for 2024.
Via
Benzinga
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
What's Going On With BridgeBio Pharma Stock On Monday?
March 04, 2024
BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted.
Via
Benzinga
Exposures
Product Safety
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
March 04, 2024
BridgeBio will receive a tiered royalty on sales that begins at the low-30% range.
Via
Investor's Business Daily
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
March 01, 2024
On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks.
Via
InvestorPlace
3 Overextended Stocks That Need to Slash Their Dividends ASAP
February 27, 2024
The most common attribute of overextended stocks other than carrying too much debt is dividends that are too big.
Via
InvestorPlace
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
February 11, 2024
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China...
Via
Talk Markets
Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial
January 30, 2024
Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Glyphosate
Legal
Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout
January 29, 2024
"Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses, and punitive damages.
Via
Benzinga
Exposures
Glyphosate
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.